曲妥珠单抗-德鲁替康(T-DXd)相关间质性肺病的胸部CT:放射科医生要点
本文综述T-DXd相关间质性肺病的胸部CT影像特征,T-DXd相关ILD发生率为10-12%。放射科医生需识别机化性肺炎(最常见)、弥漫性肺泡损伤、过敏性肺炎和非特异性间质性肺炎等模式,并注意与疾病进展、感染等鉴别。
要点
- T-DXd相关ILD发生率为10-12%,机化性肺炎是最常见的CT模式。
- 需识别的CT模式包括机化性肺炎、弥漫性肺泡损伤、过敏性肺炎和非特异性间质性肺炎。
- 有既往影像对比时对鉴别疾病进展、感染和其他情况至关重要。
核心结论
- 放射科医生应识别T-DXd相关ILD的CT模式(机化性肺炎最常见,其次为弥漫性肺泡损伤、过敏性肺炎和非特异性间质性肺炎),并警惕少见表现和鉴别诊断;有既往影像对比对鉴别疾病进展、感染和其他情况至关重要,放射科医生与肿瘤科医生的紧密协作对早期发现ILD、准确诊断和优化患者管理至关重要。
研究设计与样本
- 综述,基于临床试验和真实世界数据,总结T-DXd相关ILD的胸部CT影像特征、图像解读和鉴别诊断的实用指导。
关键影像表现/征象
- T-DXd相关ILD的CT模式包括机化性肺炎(最常见)、弥漫性肺泡损伤、过敏性肺炎和非特异性间质性肺炎。
- 需警惕较少见的表现和鉴别诊断。
诊断标准与关键数值
- T-DXd相关ILD发生于10-12%的患者。
临床应用与阅片要点
- 放射科医生在多学科团队中负责检测、描述和监测胸部CT上的ILD。
- 有既往影像对比时,有助于鉴别疾病进展、感染和其他情况。
- CT影像支持评估患者是否适合T-DXd治疗、治疗期间的主动监测以及ILD的再评估。
- 放射科医生与肿瘤科医生紧密协作对早期发现ILD、准确诊断和优化患者管理至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Trastuzumab-deruxtecan (T-DXd) is an antibody-drug conjugate targeting HER2, increasingly used to treat advanced HER2-positive tumors, including breast, gastric, lung, and colorectal cancers. Like other anticancer agents, T-DXd carries a risk of pneumotoxicity, with interstitial lung disease (ILD) occurring in 10-12% of patients. Early identification, accurate diagnosis, and appropriate management of T-DXd-related ILD are essential to optimize patient outcomes. Radiologists are key in detecting, characterizing, and monitoring ILD on chest computed tomography (CT) within a multidisciplinary care team. This review aims to familiarize radiologists with the chest CT imaging features of T-DXd-related ILD, drawing from clinical trials and real-world data. Practical guidance is provided for image interpretation and differential diagnosis, with a focus on recognizing key patterns. To support this, the review also outlines the mechanism of action of T-DXd, its clinical indications, and associated adverse events, particularly pneumotoxicity. Given the expanding use of T-DXd, radiologists must recognize ILD patterns on CT, namely organizing pneumonia (the most common), diffuse alveolar damage, hypersensitivity pneumonitis, and nonspecific interstitial pneumonia, while remaining alert to less frequent findings and differential diagnoses. When available, prior imaging for comparison is essential to differentiate disease progression, infection, and other conditions. CT imaging also supports the assessment of patient eligibility for T-DXd, proactive monitoring during treatment, and ILD reassessment. Close collaboration between radiologists and oncologists is critical for early ILD detection, accurate diagnosis, and optimal patient management.
引用
- Cereser L, Della Rossa S, Sparascio F, et al. Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: Key points for radiologists. Eur J Radiol. 2025. PMID: 41187639. doi:10.1016/j.ejrad.2025.112499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。